ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019

Geneva, Switzerland and Boston, MA -December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday December 9, 2019. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results.

Investors may participate by dialing.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
[e-mail]
[phone] Office
[phone] Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
[e-mail]
[phone] Office
[phone] Mobile

CEO Office Contact:
Shauna Dillon
[e-mail]
[phone]

Investor Contact:
Mario Corso
Senior Director, Investor Relations
[e-mail]
[phone] Office
[phone] Mobile

Attachment

• Press Release in Pdf (https://ml-eu.globenewswire.com/Resource/Download/021d8570-63e2-4a1c-b5dd-e31b9623a018)